ClinicalTrials.gg
DrugBiological

Cetuximab clinical trials

Also written Erbitux, C225 and IMC-C225.

studies test it
565
open now
67
in phase 3
71
first study started
1999

How each study uses Cetuximab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Cetuximab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
12 Feb 2004 · ERBITUX · BLA 125084 (FDA, Drugs@FDA)
European Union
29 Jun 2004 · Erbitux · EMEA/H/C/000558 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Cetuximab
440
C225 monoclonal antibody
18
monoclonal antibody C225
18
Chimeric MoAb C225
15
Chimeric Monoclonal Antibody C225
13

Brand

Erbitux
201

Development codes

C225
49
IMC-C225
42
MOAB C225
21
BMS-564717
3
RPH-002
2
LY2939777
2
NSC-714692
2
IMC-225
2

In one entry with another drug

Given together, or one or the other

FOLFIRI + Cetuximab
3
Cetuximab, Capecitabine
2
cetuximab, cisplatin
2
Capecitabine and Cetuximab
2

Biosimilars

CDP-1
2
KL 140
2
CMAB009
2

Studies by the year they started

563 studies that test it; most in 2005 (54)

Studies that test Cetuximab, by start year
YearStudies
19995
20001
20014
20021
20039
200430
200554
200641
200752
200847
200945
201039
201124
201215
201319
201412
201517
20168
201710
201817
20199
202016
202112
20227
202315
202423
202517
202614

By phase

A phase 1/2 study counts in both.

Early Phase 1
4
Phase 1
123
Phase 2
412
Phase 3
71
Phase 4
6
No phase
13

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 95 · Other 470

Eli Lilly and Company (30) · National Cancer Institute (NCI) (24) · M.D. Anderson Cancer Center (22) · Merck KGaA, Darmstadt, Germany (16) · Sun Yat-sen University (12) · Memorial Sloan Kettering Cancer Center (11) · Fudan University (10) · Alliance for Clinical Trials in Oncology (8)

Often tested with

Tested in the same studies.

Cisplatin (60) · Irinotecan (55) · Oxaliplatin (41) · Fluorouracil (41) · Bevacizumab (38) · Capecitabine (34) · Docetaxel (25) · Carboplatin (24)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 11 phase 3 studies under way

Cetuximab is the comparator. A study of two new drugs counts under both.

  • 2Petosemtamab · Genmab · next primary completion Mar 2029
  • 2Amivantamab · Janssen Research & Development, LLC · next primary completion Dec 2027
  • 1Tucatinib · Seagen, a wholly owned subsidiary of Pfizer · next primary completion Dec 2027
  • 1Trastuzumab · Seagen, a wholly owned subsidiary of Pfizer · next primary completion Dec 2027
  • 1Ipilimumab · Bristol-Myers Squibb
  • 1Nivolumab · Bristol-Myers Squibb
  • 1Bevacizumab · Azienda USL Reggio Emilia - IRCCS
  • 1Pembrolizumab · Merck Sharp & Dohme LLC · next primary completion Sep 2028
Reaching primary completion within a year · 15, 1 in phase 3

Studies that test Cetuximab, phase 3 first.

Studies

Open first, then newest update. How each study uses Cetuximab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 565

See all 565 studies that test Cetuximab →

Given beside what is tested · 297 — Cetuximab is usual care or a partner of the new treatment

Showing 20 of 297.

As the comparator · 52 — what is tested is compared with Cetuximab

Showing 20 of 52.

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call Cetuximab · ClinicalTrials.gg INT006546

  • MeSH (NLM) D000068818CetuximabConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) PQX0D8J21JCETUXIMABConfirmed FDA, NLM, Wikidata
  • RxNorm 318341Confirmed FDA, Wikidata
  • Wikidata Q420296cetuximabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C1723CetuximabOne source FDA
  • DrugBank DB00002One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.